Home

Chronic lymphocytic leukaemia (CLL) patients who are refractory or resistant to treatment can be encouraged by data showing significantly longer survival without disease progression with a treatment combining venetoclax and rituximab compared to treatment with bendamustine plus rituximab.

Peter Mac's Associate Professor Jane Oliaro and Professor Ricky Johnstone have been awarded funding for two different blood cancer research projects.

Family's loss yields new understanding of rare genetic disorder